33 million people in West Africa’s most governance-sound research environment; one of only three countries worldwide chosen for WHO’s malaria vaccine implementation programme, KHRC and NHRC’s decades-long HDSS surveillance, KCCR’s Burkitt’s lymphoma science, and FDA-Ghana’s reliable regulatory framework.
Ghana is a constitutional republic of approximately 33 million people; occupying 238,533 km² of West Africa’s Gulf of Guinea coast, bordered by Côte d’Ivoire to the west, Burkina Faso to the north, and Togo to the east; whose distinction in the clinical research landscape rests not on scale but on quality: Ghana is consistently ranked among sub-Saharan Africa’s most governance-sound, democratically stable, and operationally reliable countries, and those governance characteristics translate directly into clinical trial execution reliability that sets Ghana apart from larger but more operationally complex West African research markets. Ghana was the first sub-Saharan African country to gain independence from colonial rule (1957, under Kwame Nkrumah), and the country’s long tradition of political stability, peaceful transfers of power between the major parties (NPP and NDC), and relatively low corruption index scores; leading West Africa on Transparency International’s Corruption Perceptions Index and the Mo Ibrahim Index of African Governance; create an institutional environment in which clinical research commitments are kept, regulatory decisions are predictable, and investigator relationships persist across government transitions. Accra (~3.5–4 million metro; Gulf of Guinea coast) is Ghana’s capital, economic centre, and primary research hub, housing Korle Bu Teaching Hospital (Ghana’s largest and most research-active public hospital), the Noguchi Memorial Institute for Medical Research (one of West Africa’s most internationally connected biomedical research institutions), and the University of Ghana Medical School’s growing clinical research programmes. Kumasi (~3.5–4 million metro; Ashanti Region) is Ghana’s second city and cultural capital of the Akan-Ashanti people; home to the Komfo Anokye Teaching Hospital (KATH), the Kwame Nkrumah University of Science and Technology (KNUST), and most distinctively, the Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR): a German-Ghanaian research partnership between KNUST, KATH, and German tropical medicine institutions that has conducted internationally published research on Burkitt’s lymphoma, malaria, and tropical infectious diseases for over two decades.
Ghana’s most globally distinctive research credential is its selection; alongside Kenya and Malawi; as one of only three countries in the world chosen by WHO for the Malaria Vaccine Implementation Programme (MVIP): the first-ever real-world implementation of a licensed malaria vaccine, launched in 2019 using RTS,S/AS01 (Mosquirix) delivered through national childhood immunisation programmes; Ghana is the only West African country among the MVIP three, making every piece of Ghana’s MVIP safety, coverage, and impact data uniquely representative of West Africa’s malaria vaccine implementation context. This MVIP credential rests on decades of prior investment in Ghana’s malaria research infrastructure: the Kintampo Health Research Centre (KHRC) in Bono Region was one of the original sites for the pivotal RTS,S Phase III trial that led to WHO licensure, and the Navrongo Health Research Centre (NHRC) in the Upper East Region conducted RTS,S Phase IIb proof-of-concept research; meaning Ghana is the only country in the world whose national research infrastructure participated in the RTS,S malaria vaccine journey from Phase IIb proof-of-concept (Navrongo) through Phase III licensure-enabling efficacy trials (Kintampo/KHRC) through WHO MVIP real-world implementation, a 30-year national research continuum. Clinical trials are regulated by the Food and Drugs Authority (FDA-Ghana) under the Food and Drugs Act 2012 and GCP regulations aligned with ICH GCP E6(R2) and WHO GCP guidelines; ethics oversight is provided by institutional research ethics committees including KNUST’s Committee on Human Research, Publications and Ethics (CHRPE), the Ghana Health Service Ethical Review Committee, and institutional IRBs at major research hospitals; English is the language of all regulatory submissions and clinical research management.
Ghana’s 33 million people comprise a rich diversity of ethnic and linguistic communities whose geographic distribution maps directly onto Ghana’s research ecology: the Akan (~48%; including Ashanti in Kumasi and the Ashanti Region, Fante on the Central Region coast, Akuapem and Akyem in the Eastern Region); whose forest-zone homeland spans central and southern Ghana, carrying malaria transmission patterns characteristic of tropical forest ecology and whose Ashanti heartland hosts KCCR’s Burkitt’s lymphoma and tropical medicine research; the Mole-Dagbani, Mamprusi, and Frafra communities of the north (~17%; Tamale, Upper East, Upper West regions); whose Sahelo-sudanic ecology carries seasonal malaria transmission patterns distinct from the south, whose Navrongo HDSS population has been one of sub-Saharan Africa’s most intensively studied community health populations since 1993, and whose northern Ghana location provides research access to Burkina Faso border-region health dynamics directly relevant to West African malaria elimination programme planning; the Ewe (~14%; Volta Region, Eastern Region east); whose Volta River basin ecology and proximity to Togo create a distinct epidemiological corridor for infectious disease research; and the Ga-Dangme (~7%; Greater Accra Region coast); whose Accra peri-urban communities form the patient catchment of Korle Bu Teaching Hospital and the Noguchi Institute’s research programmes. Ghana’s pharmacogenomic profile reflects the West African Bantu and Kwa language-family genetic background shared broadly across the Akan populations; including elevated frequencies of CYP2D6*17 (affects codeine, tramadol, tamoxifen, and antidepressant metabolism), CYP2B6*6 (~35–50% of alleles; clinically important for efavirenz and nevirapine ARV metabolism), and G6PD deficiency (~15–20% of males; relevant for malaria drug safety, dapsone, and nitrofurantoin prescribing); creating a West African pharmacogenomic research environment whose population genetics are distinct from but genomically related to Nigeria’s Yoruba and Igbo HapMap reference populations. Community engagement is among Ghana’s most underappreciated research assets: the Navrongo HDSS community’s participation in the landmark Navrongo Community Health and Family Planning (CHFP) trial; which proved that community health workers can reduce childhood mortality by 25–54%; established northern Ghana as one of the most carefully characterised and research-engaged communities in sub-Saharan Africa, creating a rural research participation culture that reduces the community trust barriers that often slow rural site activation in African countries without longstanding community research relationships.
Ghana’s disease burden spans a classic West African tropical infectious disease profile overlaid with a rapidly growing urban NCD epidemic. Malaria; approximately 5–6 million clinical cases annually, representing roughly 3% of global malaria burden; is the leading cause of outpatient consultations and a major driver of childhood and maternal mortality; Ghana’s two distinct malaria ecologies (forest-zone perennial transmission in the south and Sahelo-savannah seasonal transmission in the north) create a within-country malaria research diversity that complements the KHRC-NHRC dual HDSS research infrastructure. Childhood infectious diseases; including pneumococcal disease, rotavirus, measles, and neonatal sepsis; carry significant burden in Ghana’s relatively young population (median age ~21 years) and have been extensively studied through the KHRC and NHRC HDSS systems and the Noguchi Institute’s virology and vaccine research programmes. Burkitt’s lymphoma (BL); a fast-growing B-cell malignancy endemic in the sub-Saharan African lymphoma belt where Epstein-Barr Virus (EBV) and Plasmodium falciparum malaria co-occur; is a specific cancer research niche for which Ghana’s KCCR/KATH Kumasi platform is internationally recognised; KCCR’s German BNI partnership has published BL epidemiology, pathogenesis, and treatment research that makes Ghana one of West Africa’s most important sites for paediatric BL Phase II–III research. NCDs; hypertension (~30% of adults by some estimates), Type 2 diabetes (growing urban burden), cardiovascular disease, and cervical cancer; are Ghana’s fastest-growing research opportunity as the country urbanises rapidly and its middle class expands in Accra and Kumasi.
KHRC, NHRC, and Ghana’s 30-year malaria vaccine research continuum; the only country in the world that carried RTS,S from Phase IIb proof-of-concept to Phase III licensure to WHO real-world implementation in the same national research infrastructure: Ghana’s MVIP selection by WHO; alongside Kenya and Malawi; as one of only three countries to pilot the world’s first licensed malaria vaccine (RTS,S/AS01; Mosquirix) in real-world health system implementation from 2019 onwards is the credential that most distinctively positions Ghana in the global malaria research hierarchy; but the MVIP is not an isolated achievement; it is the culmination of a 30-year national malaria research investment built through two exceptional rural health research institutions. The Navrongo Health Research Centre (NHRC) in Ghana’s Upper East Region; near the Burkina Faso border, established in 1992; was the site of the original RTS,S Phase IIb proof-of-concept trials in the 1990s and early 2000s that first demonstrated a partial protective efficacy of the candidate malaria vaccine in African children; NHRC’s community-based research infrastructure; built through the Navrongo HDSS which has tracked the health outcomes of approximately 150,000+ northern Ghanaians continuously since 1993; provided the deeply characterised, community-engaged rural research environment that established RTS,S’s early proof-of-concept. The Kintampo Health Research Centre (KHRC) in Bono Region; at the geographic centre of Ghana, established in 1994; was one of the pivotal sites for the landmark RTS,S Phase III efficacy trial (2009–2014) whose results, published in Lancet, demonstrated 39% reduction in clinical malaria in young children and led to WHO’s licensure recommendation in 2021; KHRC’s Kintampo HDSS; tracking the demographic and health dynamics of the Bono Region’s forest-zone population since 1994; provided the forest-zone malaria ecology complement to NHRC’s Sahelo-savannah northern research, together covering the range of West African malaria transmission ecologies within which the Phase III vaccine efficacy data was generated. The WHO MVIP implementation from 2019; delivering RTS,S through Ghana’s national EPI childhood immunisation programme in selected districts of the Bono, Volta, and other regions; then generated the real-world safety, coverage, and impact data that complemented the Phase III efficacy data, completing a research-to-implementation evidence chain that no other country possesses in its entirety for any malaria vaccine. For sponsors developing next-generation malaria vaccines, adjuvant systems, combination approaches, or implementation science tools for malaria vaccine delivery: Ghana’s KHRC-NHRC research infrastructure provides the most complete malaria vaccine research continuum in West Africa; the experienced investigator teams who conducted Phase IIb, Phase III, and MVIP implementation research in the same national institutional framework, with the longitudinal HDSS cohorts whose two to three decades of continuous demographic, health, and malaria exposure data create the population research context in which next-generation vaccine immunogenicity and efficacy can be most precisely assessed against the prior RTS,S baseline.
Ghana’s research proposition is West Africa’s clearest quality-over-quantity argument: FDA-Ghana’s regulatory reliability, Ghana’s institutional stability, the KHRC-NHRC dual HDSS malaria research infrastructure, KCCR’s internationally published tropical medicine and Burkitt’s lymphoma science, and the Noguchi Institute’s biomedical research capabilities together create a research environment whose per-study execution quality and regulatory predictability exceed the West African average; the argument for Ghana as the rigour anchor of West African research portfolios, complementary to Nigeria’s volume engine, in exactly the way that Ghana as the Gold Coast earned its name.
Food and Drugs Authority (FDA-Ghana) clinical trial authorisation under ICH GCP E6(R2) and WHO GCP-aligned regulations; Committee on Human Research, Publications and Ethics (CHRPE) at KNUST; Ghana Health Service Ethical Review Committee; institutional IRBs at Korle Bu, KATH, KHRC, NHRC, and Noguchi; Pan African Clinical Trial Registry (PACTR) or ICH-recognised registry registration; English-language regulatory submissions; FDA-Ghana considered one of West Africa’s most predictable and process-sound regulatory authorities; Ghana’s democratic governance stability; peaceful transfers of power between NPP and NDC governments; ensures regulatory and institutional continuity across political cycles that protects multi-year clinical trial programme investments.
GHS depreciation (~12–15 GHS/USD) makes Ghana cost-competitive for USD/EUR-denominated trial budgets; per-patient costs competitive with Kenya and Nigeria; large English-speaking physician investigator and research coordinator workforce trained at University of Ghana and KNUST medical schools; Accra’s Kotoka International Airport with direct connections to London, Amsterdam, Dubai, and Addis Ababa; KHRC and NHRC rural research stations provide community-based trial infrastructure at significantly lower cost than urban academic hospital programmes; established CRO presence in Accra and Kumasi (IQVIA, ICON, Parexel West Africa) reducing first-site activation overhead for international sponsors.
33M with significant malaria burden (5–6M cases/year; dual forest-zone + Sahel ecology); KHRC Kintampo HDSS (~150K population; RTS,S Phase III site; forest-zone central Ghana); NHRC Navrongo HDSS (~150K+ population; Sahelo-savannah; RTS,S Phase IIb; 30+ years continuous); MVIP implementation context (2019–ongoing); KCCR Burkitt’s lymphoma platform (Kumasi; EBV+malaria co-factor ecology); Noguchi Institute virology and emerging pathogen research; growing NCD burden (hypertension ~30%; T2D; cardiovascular; cervical cancer); West African Akan/Mole-Dagbani/Ewe pharmacogenomics (CYP2D6*17; CYP2B6*6; G6PD deficiency).
KHRC (Kintampo; RTS,S Phase III site; HDSS; malaria; child health; central Ghana); NHRC (Navrongo; RTS,S Phase IIb; oldest sub-Saharan HDSS; community health; northern Ghana); KCCR (Kumasi; KNUST/KATH/German BNI; tropical medicine; BL; malaria); Noguchi Memorial Institute (University of Ghana Legon; West Africa biomedical research; WHO/CDC/NIH partnerships); Korle Bu Teaching Hospital (Accra; national referral; University of Ghana); Komfo Anokye Teaching Hospital (Kumasi; KNUST; KCCR host); FDA-Ghana advancing regulatory infrastructure; growing Accra-Kumasi CRO ecosystem.
Malaria; anchored by the KHRC-NHRC-MVIP research continuum; is Ghana’s most globally validated research pillar, whose next-generation vaccine, drug, and vector control product development pipeline can leverage both KHRC’s forest-zone central Ghana patient populations (RTS,S Phase III legacy cohort and institutional expertise) and NHRC’s Sahelo-savannah northern Ghana populations (RTS,S Phase IIb legacy and 30-year HDSS surveillance) within a single FDA-Ghana regulatory framework; as R21/Matrix-M (the Oxford/Serum Institute malaria vaccine) moves through Phase III and WHO evaluation, Ghana’s KHRC and NHRC are positioned as the West African reference sites for next-generation malaria vaccine efficacy assessment. Childhood infectious diseases and vaccines constitute Ghana’s second major research pillar: the KHRC and NHRC HDSS systems; tracking 150,000+ individuals continuously since the mid-1990s; have accumulated decades of childhood mortality, vaccine coverage, malaria, pneumococcal, rotavirus, and neonatal infection data whose longitudinal depth enables vaccine immunogenicity and effectiveness studies with historical comparison baseline data that no new research site can replicate; Ghana participated in the GAVI-funded pneumococcal conjugate vaccine (PCV) introduction evaluation that provided West Africa’s primary evidence base for PCV impact, conducted through KHRC and NHRC surveillance; and Ghana’s EPI immunisation programme; strengthened through the MVIP implementation infrastructure; creates the national vaccine delivery research context that makes Ghana the natural site for any new WHO EPI candidate vaccine real-world implementation study in West Africa. Burkitt’s lymphoma (BL) is Ghana’s most specific oncology research niche: the EBV-malaria co-factor hypothesis for endemic BL; whereby sustained childhood Plasmodium falciparum infection impairs EBV immune control, allowing EBV-driven B-cell transformation and BL development; is most directly testable in populations where both EBV seroprevalence approaches 100% and malaria transmission is intense and sustained; KCCR’s Kumasi forest-zone location provides exactly this ecology, and KCCR’s two-decade BL research programme in partnership with the German Bernhard Nocht Institute (BNI) has produced internationally published BL epidemiology, pathogenesis, and chemotherapy response data (published in Blood, British Journal of Haematology, and EBioMedicine) that positions KCCR as West Africa’s reference BL research site and a natural Phase II–III partner for sponsors developing anti-EBV therapies, BL chemotherapy regimens, or novel BL diagnostics. HIV/AIDS (approximately 350,000 PLHIV in Ghana; one of West Africa’s lower national prevalences, at approximately 1.7% of adults), tropical medicine (leishmaniasis, schistosomiasis, African trypanosomiasis, and Buruli ulcer), NCDs (hypertension, T2D, cardiovascular disease, cervical cancer), and pharmacogenomics (West African Akan, Mole-Dagbani, and Ewe population CYP2D6*17 and CYP2B6*6 profiles) complete a therapeutic landscape whose malaria and BL anchors are Ghana’s most globally irreplaceable contributions and whose NCD and HIV components offer growing commercial Phase II–III opportunities.
Ghana’s research geography follows two urban corridors and two rural research stations: Accra (Korle Bu Teaching Hospital, Noguchi Institute, University of Ghana Hospital) concentrates NCD, HIV, and virology research in the capital’s 4 million-person metropolitan population; Kumasi (Komfo Anokye Teaching Hospital, KCCR) houses Ghana’s tropical medicine and Burkitt’s lymphoma research platform in the Ashanti forest zone; Kintampo (KHRC, Bono Region) provides the central Ghana HDSS and RTS,S Phase III legacy malaria research infrastructure; and Navrongo (NHRC, Upper East Region) provides the northern Ghana HDSS and the continent’s oldest continuously running sub-Saharan community health surveillance system. Secondary research activity occurs at regional teaching hospitals in Cape Coast, Tamale, and Takoradi.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Korle Bu Teaching Hospital (KBTH) | Accra | Ghana’s national referral hospital and largest public healthcare institution; established 1923, affiliated with the University of Ghana Medical School; with Phase I–IV commercial and investigator-initiated trial activity across haematology and oncology (sickle cell, Burkitt’s lymphoma Accra complement to KCCR), cardiovascular, metabolic disease, HIV, malaria, and internal medicine; Korle Bu’s position as Ghana’s national referral centre creates patient catchment spanning all of Ghana’s 16 regions, concentrating the country’s most complex disease cases in a single institution whose investigator community; affiliated with the University of Ghana Medical School’s clinical faculties; publishes research in Lancet Global Health, Malaria Journal, and other international journals; its Korle Bu Teaching Hospital Research Ethics Committee provides GCP-standard ethics oversight for all commercial Phase II–III programme applications and has processed ethics submissions from major international pharmaceutical and CRO partners; for sponsors designing Accra-based urban NCD, oncology, or infectious disease trials, Korle Bu’s scale; as Ghana’s largest hospital; provides the patient enrollment volume anchor that rural HDSS sites complement but cannot replace for therapeutic Phase II–III programmes requiring large acute-care patient populations. |
| 02 | Noguchi Memorial Institute for Medical Research (NMIMR) | Legon, Accra | One of West Africa’s most internationally connected biomedical research institutions; located on the University of Ghana’s Legon campus in Accra, named after Japanese bacteriologist Hideyo Noguchi, and operating as part of the University of Ghana with WHO collaborating centre status, CDC partnership, and NIH grant relationships; conducting research across malaria (molecular epidemiology, drug resistance surveillance, antigen discovery), HIV (virology, transmission dynamics, ART research), emerging and re-emerging viral pathogens (Lassa fever, Ebola, SARS-CoV-2 genomics), neglected tropical diseases, and vaccine immunology; NMIMR’s BSL-2+ laboratory infrastructure; including molecular biology, virology, flow cytometry, and next-generation sequencing capabilities; provides the translational research platform that enables complex biomarker sub-studies within commercial Phase II–III trials at adjacent Korle Bu Teaching Hospital and across Ghana’s national research network; NMIMR’s WHO collaborating centre status and CDC partnership create the international governance credibility that FDA and regulatory reviewers assess when evaluating the laboratory data quality of Ghana-generated biomarker and pharmacokinetic sub-studies within multinational regulatory submissions. |
| 03 | Kintampo Health Research Centre (KHRC) | Kintampo, Bono Region | Ghana’s most internationally distinguished rural health research institution; operating from Kintampo at the geographic centre of Ghana since 1994, under the Ghana Health Service; and one of the pivotal sites for the RTS,S/AS01 malaria vaccine Phase III efficacy trial (2009–2014) whose Lancet-published results established 39% protective efficacy in young children and enabled WHO licensure in 2021; KHRC’s Kintampo Health and Demographic Surveillance System (KHDSS) tracks the health outcomes of approximately 150,000 individuals in the Kintampo North and South Districts of the Bono Region; providing longitudinal malaria exposure, childhood mortality, nutrition, maternal health, and immunisation coverage data accumulated continuously since the mid-1990s; Phase II–IV malaria vaccine and drug trials (the preferred West African forest-zone malaria research site for any sponsor building on or comparing with the RTS,S Phase III evidence base), childhood infectious disease and vaccine implementation research, and maternal and neonatal health programmes reflecting the KHDSS’ comprehensive coverage of the Bono Region’s rural forest-zone population; KHRC’s established MVIP implementation experience from Ghana’s 2019–ongoing malaria vaccine real-world rollout creates the site team expertise in operational malaria vaccine research that no other West African institution yet possesses at Phase III quality. |
| 04 | Navrongo Health Research Centre (NHRC) | Navrongo, Upper East | One of sub-Saharan Africa’s oldest and most carefully maintained health research institutions; established in Navrongo in the Upper East Region near the Burkina Faso border in 1992, under the Ghana Health Service; and the site of the original RTS,S Phase IIb proof-of-concept malaria vaccine trials in the 1990s and early 2000s whose data first established the scientific plausibility of a partially protective malaria vaccine in African children; NHRC’s Navrongo HDSS has tracked the demographic and health dynamics of approximately 150,000+ residents of the Kassena-Nankana Districts continuously since 1993; making it one of sub-Saharan Africa’s longest-running community surveillance systems and the institution whose landmark Navrongo Community Health and Family Planning (CHFP) trial proved that community health workers can reduce childhood mortality by 25–54%, one of the most replicated community health intervention findings in global health history; NHRC’s Sahelo-savannah malaria ecology; with distinctly seasonal transmission driven by the West African monsoon; provides the northern Ghana seasonal malaria research environment complementary to KHRC’s perennial forest-zone transmission; a primary partner for any sponsor developing malaria vaccine, antimalarial drug, or vector control product requiring data across both perennial and seasonal West African malaria transmission contexts within a single FDA-Ghana regulatory submission. |
| 05 | Komfo Anokye Teaching Hospital (KATH) / KCCR | Kumasi | Ghana’s second-largest teaching hospital; affiliated with the Kwame Nkrumah University of Science and Technology (KNUST) and hosting the Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR) on its campus; with Phase II–IV research activity spanning tropical medicine (Burkitt’s lymphoma; West Africa’s most active BL research programme through the KCCR/German BNI partnership; malaria epidemiology and drug trials; leishmaniasis; African tick bite fever), haematology, oncology, HIV, and internal medicine; KATH’s Kumasi Ashanti Region patient catchment; from the Akan forest zone where EBV seroprevalence approaches 100% and sustained falciparum malaria transmission creates the co-factor ecology for endemic Burkitt’s lymphoma; provides KCCR with the paediatric BL patient population whose disease is most mechanistically consistent with the EBV-malaria co-factor hypothesis; for sponsors developing anti-EBV therapeutics, novel BL chemotherapy regimens, BL diagnostics, or cancer immunotherapies targeting EBV+ malignancies, KCCR/KATH Kumasi is West Africa’s only site with two decades of dedicated BL molecular epidemiology, pathogenesis, and treatment research published in Blood, British Journal of Haematology, and EBioMedicine. |
| 06 | Kumasi Centre for Collaborative Research (KCCR); KNUST | Kumasi | Ghana’s most internationally published tropical medicine research institution; a German-Ghanaian research partnership between KNUST, KATH, and German tropical medicine institutes (originally associated with the Bernhard Nocht Institute for Tropical Medicine, Hamburg); conducting research on Burkitt’s lymphoma (the primary paediatric B-cell malignancy endemic to sub-Saharan Africa’s malaria-endemic zones; KCCR’s published BL research spans epidemiology, EBV co-factor biology, chemotherapy regimens, and translational immunology), malaria (drug resistance surveillance, pharmacokinetics, clinical trials), HIV, and tropical infectious diseases; KCCR’s German partnership provides molecular biology, next-generation sequencing, and advanced immunology laboratory infrastructure that extends beyond what KATH’s clinical research infrastructure alone provides; creating a translational research capability in Kumasi whose combined clinical and laboratory research output has produced more internationally published West African tropical medicine research per institutional size than any comparable institution in the region; KCCR’s KNUST affiliation provides the academic investigator community whose research training, grant management, and ICH GCP compliance oversight form the institutional research governance that commercial Phase II–III sponsors require for BL, malaria, and tropical medicine trial activation at the Kumasi site. |
| 07 | University of Ghana Hospital (UGH); UGMS | Legon, Accra | The University of Ghana Medical School’s on-campus hospital; established on the Legon university campus to provide training hospital facilities for the University of Ghana Medical School’s clinical undergraduate and postgraduate programmes and serving as a research-active academic medical facility for the Legon academic community; with Phase II–III commercial and investigator-initiated trial activity across internal medicine, cardiovascular, metabolic disease, HIV, and malaria; UGH’s Legon campus location in Accra’s academic corridor; adjacent to the Noguchi Memorial Institute and within the University of Ghana research community; creates a natural research cluster whose biomedical science, clinical pharmacology, and public health faculty investigator community provides the academic research governance and grant management infrastructure that supports complex pharmacokinetic sub-studies, biomarker studies, and immunology research alongside UGH’s clinical trial patient recruitment; an important Accra academic research complement to Korle Bu’s larger national referral volume and the Noguchi Institute’s laboratory science capabilities within multi-site Accra research designs. |
| 08 | Tamale Teaching Hospital (TTH) | Tamale, Northern Region | Northern Ghana’s primary academic teaching hospital; affiliated with the University for Development Studies (UDS) Faculty of Medicine and serving as the referral centre for the Northern, Savannah, and North East Regions’ approximately 4 million people; with Phase II–III research activity across malaria (northern Ghana’s seasonal malaria transmission; NHRC Navrongo research network extension into Tamale’s urban corridor), meningococcal meningitis (northern Ghana is part of the sub-Saharan “meningitis belt” spanning the Sahel; providing a specific northern Ghana meningococcal disease research population complementary to the southern malaria-dominant ecology), HIV, and internal medicine; TTH’s Tamale location in the Dagbon cultural heartland; capital of the Mole-Dagbani peoples whose Sahelo-sudanic ecology and Islamic cultural context differ substantially from Accra’s and Kumasi’s Akan forest-zone populations; provides pharmacogenomic and cultural context diversity within a single Ghanaian regulatory submission that reflects northern Ghana’s distinct population genetics and disease ecology. |
| 09 | Cape Coast Teaching Hospital (CCTH) | Cape Coast, Central Region | The academic hospital of the University of Cape Coast (UCC) School of Medical Sciences; in Ghana’s historical colonial capital and the seat of the first British fort in West Africa; with Phase II–III research activity across malaria (the Central Region’s Guinea coast ecology carries year-round malaria transmission; Cape Coast’s coastal-urban epidemiological profile differs from both Accra’s metropolitan catchment and KHRC’s deep rural forest-zone), cardiovascular, oncology, and internal medicine; Cape Coast Teaching Hospital’s University of Cape Coast affiliation creates a growing academic investigator community whose health sciences research programme; including collaborations with the UCC School of Public Health and the Cape Coast HDSS; is producing published malaria, maternal health, and cardiovascular epidemiology from the Central Region’s Fante-dominated coastal population; an important coastal Ghana research complement to KHRC’s inland forest-zone and Korle Bu’s Accra metropolitan research corridors for sponsors designing Phase III programmes requiring coastal Central Region patient coverage. |
| 10 | Effia-Nkwanta Regional Teaching Hospital | Sekondi-Takoradi, Western Region | The Western Region’s primary academic and regional referral hospital; in Sekondi-Takoradi, Ghana’s third-largest urban area and the hub of Ghana’s offshore oil industry (Jubilee Field production since 2010); with Phase II–III research activity across internal medicine, cardiovascular (the oil-industry economic profile creates elevated cardiovascular and occupational health disease patterns relevant to NCD research), malaria (Western Region’s forest-zone ecology complements KHRC’s Bono Region research), and surgical oncology; Effia-Nkwanta’s Western Region location provides research access to the Ahanta and Nzema coastal communities; distinct Akan sub-groups with historical Atlantic trade relationships whose genetic background and disease ecology reflect the Western Region’s specific position between the Central Region’s Fante coast and the Ivorian border; alongside the Takoradi oil industry workforce whose specific occupational health and NCD profile creates a research population not replicated at Accra’s academic hospital sites. |
| 11 | Ho Teaching Hospital | Ho, Volta Region | The Volta Region’s primary academic hospital; in Ho, capital of the Volta Region and the cultural centre of Ghana’s Ewe-speaking population near the Togo border; with Phase II–III research activity across malaria, HIV (the Volta Region’s Ewe-speaking corridor including Hohoe and Keta carries HIV prevalence rates somewhat above the national average, related to cross-border mobility with Togo and Benin), cardiovascular, and internal medicine; Ho Teaching Hospital’s Volta Region location provides research access to the Ewe population; whose genetic ancestry, pharmacogenomic profile, and epidemiological context differ from the Akan-dominant western and Mole-Dagbani northern corridors; creating within-Ghana West African population diversity for CYP2D6 and CYP2B6 pharmacogenomic sub-studies across Akan, Ewe, and Mole-Dagbani ancestry groups; Ho’s proximity to the Ghana-Togo border creates a natural entry point for sponsors designing cross-border West African Phase III programmes integrating Ghana and Togo data within coordinated West African regulatory submissions. |
| 12 | Sunyani Teaching Hospital | Sunyani, Bono Region | The Bono Region’s urban academic hospital; in Sunyani, the administrative capital of the Bono Region and the closest major urban centre to the Kintampo Health Research Centre; providing the urban Bono Region patient catchment complement to KHRC’s rural forest-zone research for sponsors designing integrated KHRC-plus-urban-Bono Region Phase III programs; Phase II–III research activity across malaria (Bono Region forest-zone continuous malaria transmission; urban Sunyani complement to rural Kintampo’s HDSS population), child health, maternal health, and internal medicine; Sunyani Teaching Hospital’s geographic proximity to KHRC in Kintampo; approximately 95km north; creates a natural urban–rural paired research design option within the Bono Region for sponsors whose Phase III malaria or child health protocols require both community-based HDSS enrollment through KHRC and hospital-based acute-care patient enrollment through a nearby urban site within the same regional ecology and patient population demographics. |
Ghana’s national referral hospital and largest public healthcare institution; established 1923, affiliated with the University of Ghana Medical School; with Phase I–IV commercial and investigator-initiated trial activity across haematology and oncology (sickle cell, Burkitt’s lymphoma Accra complement to KCCR), cardiovascular, metabolic disease, HIV, malaria, and internal medicine; Korle Bu’s position as Ghana’s national referral centre creates patient catchment spanning all of Ghana’s 16 regions, concentrating the country’s most complex disease cases in a single institution whose investigator community; affiliated with the University of Ghana Medical School’s clinical faculties; publishes research in Lancet Global Health, Malaria Journal, and other international journals; its Korle Bu Teaching Hospital Research Ethics Committee provides GCP-standard ethics oversight for all commercial Phase II–III programme applications and has processed ethics submissions from major international pharmaceutical and CRO partners; for sponsors designing Accra-based urban NCD, oncology, or infectious disease trials, Korle Bu’s scale; as Ghana’s largest hospital; provides the patient enrollment volume anchor that rural HDSS sites complement but cannot replace for therapeutic Phase II–III programmes requiring large acute-care patient populations.
One of West Africa’s most internationally connected biomedical research institutions; located on the University of Ghana’s Legon campus in Accra, named after Japanese bacteriologist Hideyo Noguchi, and operating as part of the University of Ghana with WHO collaborating centre status, CDC partnership, and NIH grant relationships; conducting research across malaria (molecular epidemiology, drug resistance surveillance, antigen discovery), HIV (virology, transmission dynamics, ART research), emerging and re-emerging viral pathogens (Lassa fever, Ebola, SARS-CoV-2 genomics), neglected tropical diseases, and vaccine immunology; NMIMR’s BSL-2+ laboratory infrastructure; including molecular biology, virology, flow cytometry, and next-generation sequencing capabilities; provides the translational research platform that enables complex biomarker sub-studies within commercial Phase II–III trials at adjacent Korle Bu Teaching Hospital and across Ghana’s national research network; NMIMR’s WHO collaborating centre status and CDC partnership create the international governance credibility that FDA and regulatory reviewers assess when evaluating the laboratory data quality of Ghana-generated biomarker and pharmacokinetic sub-studies within multinational regulatory submissions.
Ghana’s most internationally distinguished rural health research institution; operating from Kintampo at the geographic centre of Ghana since 1994, under the Ghana Health Service; and one of the pivotal sites for the RTS,S/AS01 malaria vaccine Phase III efficacy trial (2009–2014) whose Lancet-published results established 39% protective efficacy in young children and enabled WHO licensure in 2021; KHRC’s Kintampo Health and Demographic Surveillance System (KHDSS) tracks the health outcomes of approximately 150,000 individuals in the Kintampo North and South Districts of the Bono Region; providing longitudinal malaria exposure, childhood mortality, nutrition, maternal health, and immunisation coverage data accumulated continuously since the mid-1990s; Phase II–IV malaria vaccine and drug trials (the preferred West African forest-zone malaria research site for any sponsor building on or comparing with the RTS,S Phase III evidence base), childhood infectious disease and vaccine implementation research, and maternal and neonatal health programmes reflecting the KHDSS’ comprehensive coverage of the Bono Region’s rural forest-zone population; KHRC’s established MVIP implementation experience from Ghana’s 2019–ongoing malaria vaccine real-world rollout creates the site team expertise in operational malaria vaccine research that no other West African institution yet possesses at Phase III quality.
One of sub-Saharan Africa’s oldest and most carefully maintained health research institutions; established in Navrongo in the Upper East Region near the Burkina Faso border in 1992, under the Ghana Health Service; and the site of the original RTS,S Phase IIb proof-of-concept malaria vaccine trials in the 1990s and early 2000s whose data first established the scientific plausibility of a partially protective malaria vaccine in African children; NHRC’s Navrongo HDSS has tracked the demographic and health dynamics of approximately 150,000+ residents of the Kassena-Nankana Districts continuously since 1993; making it one of sub-Saharan Africa’s longest-running community surveillance systems and the institution whose landmark Navrongo Community Health and Family Planning (CHFP) trial proved that community health workers can reduce childhood mortality by 25–54%, one of the most replicated community health intervention findings in global health history; NHRC’s Sahelo-savannah malaria ecology; with distinctly seasonal transmission driven by the West African monsoon; provides the northern Ghana seasonal malaria research environment complementary to KHRC’s perennial forest-zone transmission; a primary partner for any sponsor developing malaria vaccine, antimalarial drug, or vector control product requiring data across both perennial and seasonal West African malaria transmission contexts within a single FDA-Ghana regulatory submission.
Ghana’s second-largest teaching hospital; affiliated with the Kwame Nkrumah University of Science and Technology (KNUST) and hosting the Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR) on its campus; with Phase II–IV research activity spanning tropical medicine (Burkitt’s lymphoma; West Africa’s most active BL research programme through the KCCR/German BNI partnership; malaria epidemiology and drug trials; leishmaniasis; African tick bite fever), haematology, oncology, HIV, and internal medicine; KATH’s Kumasi Ashanti Region patient catchment; from the Akan forest zone where EBV seroprevalence approaches 100% and sustained falciparum malaria transmission creates the co-factor ecology for endemic Burkitt’s lymphoma; provides KCCR with the paediatric BL patient population whose disease is most mechanistically consistent with the EBV-malaria co-factor hypothesis; for sponsors developing anti-EBV therapeutics, novel BL chemotherapy regimens, BL diagnostics, or cancer immunotherapies targeting EBV+ malignancies, KCCR/KATH Kumasi is West Africa’s only site with two decades of dedicated BL molecular epidemiology, pathogenesis, and treatment research published in Blood, British Journal of Haematology, and EBioMedicine.
Ghana’s most internationally published tropical medicine research institution; a German-Ghanaian research partnership between KNUST, KATH, and German tropical medicine institutes (originally associated with the Bernhard Nocht Institute for Tropical Medicine, Hamburg); conducting research on Burkitt’s lymphoma (the primary paediatric B-cell malignancy endemic to sub-Saharan Africa’s malaria-endemic zones; KCCR’s published BL research spans epidemiology, EBV co-factor biology, chemotherapy regimens, and translational immunology), malaria (drug resistance surveillance, pharmacokinetics, clinical trials), HIV, and tropical infectious diseases; KCCR’s German partnership provides molecular biology, next-generation sequencing, and advanced immunology laboratory infrastructure that extends beyond what KATH’s clinical research infrastructure alone provides; creating a translational research capability in Kumasi whose combined clinical and laboratory research output has produced more internationally published West African tropical medicine research per institutional size than any comparable institution in the region; KCCR’s KNUST affiliation provides the academic investigator community whose research training, grant management, and ICH GCP compliance oversight form the institutional research governance that commercial Phase II–III sponsors require for BL, malaria, and tropical medicine trial activation at the Kumasi site.
The University of Ghana Medical School’s on-campus hospital; established on the Legon university campus to provide training hospital facilities for the University of Ghana Medical School’s clinical undergraduate and postgraduate programmes and serving as a research-active academic medical facility for the Legon academic community; with Phase II–III commercial and investigator-initiated trial activity across internal medicine, cardiovascular, metabolic disease, HIV, and malaria; UGH’s Legon campus location in Accra’s academic corridor; adjacent to the Noguchi Memorial Institute and within the University of Ghana research community; creates a natural research cluster whose biomedical science, clinical pharmacology, and public health faculty investigator community provides the academic research governance and grant management infrastructure that supports complex pharmacokinetic sub-studies, biomarker studies, and immunology research alongside UGH’s clinical trial patient recruitment; an important Accra academic research complement to Korle Bu’s larger national referral volume and the Noguchi Institute’s laboratory science capabilities within multi-site Accra research designs.
Northern Ghana’s primary academic teaching hospital; affiliated with the University for Development Studies (UDS) Faculty of Medicine and serving as the referral centre for the Northern, Savannah, and North East Regions’ approximately 4 million people; with Phase II–III research activity across malaria (northern Ghana’s seasonal malaria transmission; NHRC Navrongo research network extension into Tamale’s urban corridor), meningococcal meningitis (northern Ghana is part of the sub-Saharan “meningitis belt” spanning the Sahel; providing a specific northern Ghana meningococcal disease research population complementary to the southern malaria-dominant ecology), HIV, and internal medicine; TTH’s Tamale location in the Dagbon cultural heartland; capital of the Mole-Dagbani peoples whose Sahelo-sudanic ecology and Islamic cultural context differ substantially from Accra’s and Kumasi’s Akan forest-zone populations; provides pharmacogenomic and cultural context diversity within a single Ghanaian regulatory submission that reflects northern Ghana’s distinct population genetics and disease ecology.
The academic hospital of the University of Cape Coast (UCC) School of Medical Sciences; in Ghana’s historical colonial capital and the seat of the first British fort in West Africa; with Phase II–III research activity across malaria (the Central Region’s Guinea coast ecology carries year-round malaria transmission; Cape Coast’s coastal-urban epidemiological profile differs from both Accra’s metropolitan catchment and KHRC’s deep rural forest-zone), cardiovascular, oncology, and internal medicine; Cape Coast Teaching Hospital’s University of Cape Coast affiliation creates a growing academic investigator community whose health sciences research programme; including collaborations with the UCC School of Public Health and the Cape Coast HDSS; is producing published malaria, maternal health, and cardiovascular epidemiology from the Central Region’s Fante-dominated coastal population; an important coastal Ghana research complement to KHRC’s inland forest-zone and Korle Bu’s Accra metropolitan research corridors for sponsors designing Phase III programmes requiring coastal Central Region patient coverage.
The Western Region’s primary academic and regional referral hospital; in Sekondi-Takoradi, Ghana’s third-largest urban area and the hub of Ghana’s offshore oil industry (Jubilee Field production since 2010); with Phase II–III research activity across internal medicine, cardiovascular (the oil-industry economic profile creates elevated cardiovascular and occupational health disease patterns relevant to NCD research), malaria (Western Region’s forest-zone ecology complements KHRC’s Bono Region research), and surgical oncology; Effia-Nkwanta’s Western Region location provides research access to the Ahanta and Nzema coastal communities; distinct Akan sub-groups with historical Atlantic trade relationships whose genetic background and disease ecology reflect the Western Region’s specific position between the Central Region’s Fante coast and the Ivorian border; alongside the Takoradi oil industry workforce whose specific occupational health and NCD profile creates a research population not replicated at Accra’s academic hospital sites.
The Volta Region’s primary academic hospital; in Ho, capital of the Volta Region and the cultural centre of Ghana’s Ewe-speaking population near the Togo border; with Phase II–III research activity across malaria, HIV (the Volta Region’s Ewe-speaking corridor including Hohoe and Keta carries HIV prevalence rates somewhat above the national average, related to cross-border mobility with Togo and Benin), cardiovascular, and internal medicine; Ho Teaching Hospital’s Volta Region location provides research access to the Ewe population; whose genetic ancestry, pharmacogenomic profile, and epidemiological context differ from the Akan-dominant western and Mole-Dagbani northern corridors; creating within-Ghana West African population diversity for CYP2D6 and CYP2B6 pharmacogenomic sub-studies across Akan, Ewe, and Mole-Dagbani ancestry groups; Ho’s proximity to the Ghana-Togo border creates a natural entry point for sponsors designing cross-border West African Phase III programmes integrating Ghana and Togo data within coordinated West African regulatory submissions.
The Bono Region’s urban academic hospital; in Sunyani, the administrative capital of the Bono Region and the closest major urban centre to the Kintampo Health Research Centre; providing the urban Bono Region patient catchment complement to KHRC’s rural forest-zone research for sponsors designing integrated KHRC-plus-urban-Bono Region Phase III programs; Phase II–III research activity across malaria (Bono Region forest-zone continuous malaria transmission; urban Sunyani complement to rural Kintampo’s HDSS population), child health, maternal health, and internal medicine; Sunyani Teaching Hospital’s geographic proximity to KHRC in Kintampo; approximately 95km north; creates a natural urban–rural paired research design option within the Bono Region for sponsors whose Phase III malaria or child health protocols require both community-based HDSS enrollment through KHRC and hospital-based acute-care patient enrollment through a nearby urban site within the same regional ecology and patient population demographics.
Ghana’s pharmaceutical regulatory authority; established under the Food and Drugs Act 2012 and considered one of West Africa’s most process-sound and predictable regulatory bodies; governing pharmaceutical product registration, clinical trial authorisation, and GCP compliance under ICH GCP E6(R2) and WHO GCP-aligned regulations; FDA-Ghana’s regulatory predictability reflects Ghana’s broader governance stability; approval processes are not disrupted by political transitions, regulatory officials maintain institutional continuity, and GCP inspection processes follow documented procedures; creating the operational reliability that distinguishes Ghana from larger but less institutionally stable West African research markets; FDA-Ghana’s ICH engagement pathway and active participation in African pharmaceutical regulatory harmonisation (AMRH/AUDA-NEPAD) position it as a reference regulatory authority for the ECOWAS regional framework.
Ghana’s national health service research governance body; providing institutional oversight for the Kintampo Health Research Centre (KHRC) and Navrongo Health Research Centre (NHRC) as Ghana Health Service research institutions, and coordinating the national health research ethics framework through the Ghana Health Service Ethical Review Committee; whose approvals are required for all research conducted at or through GHS-affiliated research institutions including KHRC and NHRC; GHS Research and Development Division’s institutional ownership of KHRC and NHRC means that commercial pharmaceutical company Phase II–III partnerships at these institutions require GHS institutional approval in addition to FDA-Ghana clinical trial authorisation; a governance layer that reflects Ghana’s commitment to ensuring that national research institutions serve national health priorities alongside international research partnerships.
The primary research ethics committee for KNUST-affiliated research including all KCCR trials and KATH-based commercial studies; providing GCP-standard ethics review for Phase I–IV clinical trials at KCCR and KATH through a structured IRB process aligned with WHO and ICH research ethics standards; and one of Ghana’s most experienced ethics committees, having reviewed tropical medicine, BL, malaria, HIV, and NCD trial protocols from Wellcome Trust, NIH, German DFG, and commercial pharmaceutical company sponsors for over two decades; CHRPE’s track record of reviewing complex infectious disease and oncology protocols; including KCCR’s BL molecular epidemiology studies and KATH’s malaria drug trials; provides international sponsors with the ethics governance confidence that FDA and EMA require when assessing Ghanaian site data within multinational regulatory submissions.
One of sub-Saharan Africa’s most important rural malaria and child health research centres; the RTS,S Phase III pivotal trial site whose Lancet-published data contributed to WHO licensure of the world’s first malaria vaccine; operating the Kintampo HDSS longitudinal surveillance of approximately 150,000 Bono Region residents since the mid-1990s and providing Phase II–IV malaria vaccine, drug, and implementation research capabilities within Ghana’s forest-zone perennial malaria ecology; KHRC’s MVIP implementation experience from Ghana’s 2019–ongoing RTS,S vaccine real-world rollout creates an institutional team with operational malaria vaccine research expertise spanning every stage from proof-of-concept through Phase III efficacy through real-world implementation; a 30-year malaria vaccine research journey concentrated in a single institution whose accumulated expertise is the most complete of any West African research institution.
One of sub-Saharan Africa’s oldest and most carefully characterised community health research institutions; established in Navrongo in 1992, whose Navrongo HDSS is now over 30 years old and whose Navrongo Community Health and Family Planning (CHFP) trial results have been replicated across 30+ countries; providing Phase I–IV malaria, vaccine, and community health research capabilities within Ghana’s Sahelo-savannah seasonal malaria ecology; NHRC’s RTS,S Phase IIb role; providing the original proof-of-concept data that launched the RTS,S vaccine programme; and its 30-year continuous HDSS community engagement create the northern Ghana research infrastructure whose community trust, investigator expertise, and longitudinal data depth make it irreplaceable for any malaria or child health research programme requiring seasonal northern Ghana transmission ecology and deeply characterised rural community populations.
West Africa’s most internationally published tropical medicine and Burkitt’s lymphoma research institution; a German-Ghanaian partnership between KNUST, KATH, and German tropical medicine institutes providing molecular biology, next-generation sequencing, and advanced immunology laboratory infrastructure to support translational research alongside KATH’s clinical trial capabilities; whose two-decade BL research programme (published in Blood, British Journal of Haematology, and EBioMedicine) and malaria drug and epidemiology research portfolio make it West Africa’s reference institution for EBV-associated paediatric malignancy and forest-zone Ashanti Region tropical medicine; KCCR’s German BNI academic network connects Ghana’s Kumasi research platform to European Union research funding (DFG, BMBF, Horizon Europe) and regulatory channels that create complementary EU research governance documentation alongside FDA-Ghana approvals for sponsors designing dual FDA-Ghana and EMA study documentation.
One of West Africa’s most internationally connected biomedical research institutions; a University of Ghana institute with WHO collaborating centre status, CDC partnership, and NIH grant relationships; conducting research on malaria molecular epidemiology, HIV virology, emerging pathogens (Lassa fever, Ebola, SARS-CoV-2 genomics), neglected tropical diseases, and vaccine immunology through BSL-2+ molecular biology, virology, and next-generation sequencing laboratory infrastructure; NMIMR’s WHO collaborating centre status is the international governance credential that makes its laboratory data the most internationally credible from Ghana for pharmacokinetic, biomarker, and pathogen genomics sub-studies within commercial Phase II–III multinational regulatory submissions; its CDC partnership infrastructure provides the operational quality assurance standards that US FDA reviewers recognise when assessing laboratory data provenance from West African research sites.
Global CRO with Ghana operations managed through its West Africa network; based in Accra with Kumasi field teams; supporting Phase II–IV programs across malaria (KHRC Kintampo, NHRC Navrongo, and KCCR/KATH platforms), BL oncology (KCCR), HIV (Noguchi Institute and Korle Bu networks), NCD (Korle Bu and KATH commercial portfolios), and childhood vaccines (KHRC/NHRC HDSS cohort-linked programmes); FDA-Ghana regulatory submission expertise and CHRPE/GHS Ethical Review Committee ethics application support; established investigator relationships across Korle Bu Teaching Hospital, KCCR/KATH Kumasi, KHRC Kintampo, NHRC Navrongo, and regional teaching hospitals; GHS budget management; West Africa regional coordination integrating Ghana with Nigeria, Côte d’Ivoire, and Senegal for pan-West-African Phase III programs.
International CRO with Ghana operations supporting Phase II–IV malaria (KHRC/NHRC dual HDSS platforms; MVIP implementation experience leveraged for next-generation malaria vaccine trials), Burkitt’s lymphoma (KCCR/KATH Kumasi), HIV, NCD, and tropical medicine programs; established investigator relationships across Ghana’s four primary research corridors (Accra; Korle Bu/Noguchi; Kumasi; KATH/KCCR; Kintampo; KHRC; Navrongo; NHRC) and regional teaching hospitals; specialist malaria Phase II–III trial management reflecting Ghana’s dual forest-zone plus Sahelo-savannah ecology; FDA-Ghana regulatory strategy for sponsors using Ghana as the West African anchor of pan-African malaria or paediatric infectious disease Phase III programs.
Global CRO with Ghana operations providing Phase II–III trial management and FDA-Ghana regulatory strategy across malaria, BL oncology, HIV, NCD, and pharmacogenomics indications; established site networks across Accra research corridor (Korle Bu, Noguchi, UGH), Kumasi research corridor (KATH, KCCR), Kintampo KHRC rural research station, Navrongo NHRC rural research station, and regional teaching hospitals in Tamale, Cape Coast, and Ho; biostatistics and data management for Ghanaian multi-ethnic pharmacogenomic sub-group analyses across Akan (Ashanti, Fante, Akuapim), Mole-Dagbani, and Ewe population groups; West Africa regional programme coordination spanning Ghana and Nigeria for sponsors designing complementary West African volume-and-rigour research portfolios.
International biopharmaceutical solutions company with Ghana operations providing integrated Phase I–IV clinical development services across malaria, BL oncology, HIV, childhood vaccines, and NCD indications; KHRC-NHRC dual HDSS malaria vaccine and drug trial coordination spanning Ghana’s forest-zone and Sahelo-savannah ecologies within single FDA-Ghana regulatory submissions; KCCR BL paediatric oncology programme commercial trial partnership management; GHS budget management strategies for USD-denominated sponsors; pan-West-African programme coordination integrating Ghana’s rigour-anchor research infrastructure with Nigeria’s volume-engine capacity for sponsors building comprehensive West African malaria, SCD, and infectious disease clinical development portfolios.
The Bottom Line: Ghana is West Africa’s gold standard research platform and the sub-Saharan Africa arc’s proof that research quality is not simply a function of population scale: with 33 million people; a fraction of Nigeria’s 220 million; Ghana has produced more internationally validated malaria research infrastructure per capita than almost any country in the world, including one of only three countries selected by WHO to pilot the world’s first licensed malaria vaccine outside of clinical trials. The MVIP argument is Ghana’s most globally distinctive credential: only Ghana, Kenya, and Malawi were chosen by WHO in 2019 for the RTS,S Malaria Vaccine Implementation Programme, and Ghana is the only West African country among the three; meaning every data point from Ghana’s MVIP implementation contributes uniquely to the global malaria vaccine evidence base for West Africa’s specific health system context, malaria ecology, and immunological setting. The KHRC-NHRC dual HDSS argument is Ghana’s most operationally irreplaceable: Kintampo’s forest-zone central Ghana HDSS and Navrongo’s Sahelo-savannah northern Ghana HDSS together provide the longitudinal population health surveillance architecture through which Ghana conducted RTS,S Phase IIb proof-of-concept (Navrongo), Phase III licensure-enabling efficacy (KHRC), and MVIP real-world implementation; a 30-year research continuum in the same national institutions that no other country possesses for any vaccine, making Ghana the natural West African anchor for every next-generation malaria vaccine Phase II–III programme that builds on or must compare with the RTS,S precedent. KCCR’s Burkitt’s lymphoma platform is Ghana’s most specific oncology research distinction: West Africa’s only dedicated BL research institution with 20+ years of published molecular epidemiology, EBV co-factor biology, and treatment research; positioned in Kumasi’s Ashanti forest-zone where EBV seroprevalence and sustained malaria transmission create the precise co-factor ecology in which endemic BL flourishes; makes KCCR the West African partner of choice for any anti-EBV therapeutic, novel BL chemotherapy, or cancer immunotherapy programme targeting EBV+ paediatric malignancies. The governance argument is Ghana’s most operationally decisive: in a sub-Saharan African research landscape where regulatory unpredictability, institutional instability, and political risk are genuine programme management considerations, Ghana’s position as West Africa’s governance leader; consistent democratic transfers of power, FDA-Ghana regulatory predictability, and GHS institutional continuity across government transitions; means that multi-year Phase III programme investments in Ghana face lower country risk than most comparable sub-Saharan African research markets. Ghana as the rigour anchor and Nigeria as the volume engine: these two countries are not competitors in the West African research landscape but complements; sponsors who understand West Africa build portfolios that leverage Ghana’s quality infrastructure and Nigeria’s patient scale, in the same way that well-designed East African portfolios integrate Kenya’s KEMRI research depth with Uganda’s and Tanzania’s enrollment volume. Ghana is where the world’s first licensed malaria vaccine was proved in real-world use; and that is a research credential that belongs to Ghana and Ghana alone.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.